Arthneeti

Laurus Labs Q2 FY27 Share Price & Earnings Call Analysis

₹2,405.50+7.20% today
Market cap
₹1.30L Cr
P/E
118.86
ROE
18.30%
PEG
28.22
Price to sales
17.89
Debt to equity
0.48
52W high / low
₹2,406 / ₹945
Sales growth (5Y)
7.19%
EBITDA margin
27.98%
Net profit margin
13.15%
Promoter holding
27.47%
Sales (last year)
₹7,270 Cr

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Guidance scorecard · Q2 FY27 call

What Laurus Labs Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#14of 84 in
Pharmaceuticals & Biotechnology
Revenue20–40%MarginsFlatCapexPlannedFundraisingPlannedOrder bookRising

RevenueQ1 FY27 call

20–40%
  • Laurus Labs expects to maintain the current run rate in sales with a variation of plus/minus INR100 crores.
  • Commercial sales within custom synthesis accounted for 50% in FY '26 and increased to 55% in 1Q FY '27, with expectations for growth in coming quarters and years.
  • CDMO business shows strong growth potential, with confidence in significant growth driven by existing capacity and new capex.
  • The company aims for CDMO revenue to contribute at least 50% of total turnover by FY '30.
  • Laurus Bio's revenue contribution (currently 20% from animal origin-free ingredients and 60% from early-stage CDMO molecules) is expected to ramp up significantly over the next 18-24 months.

2 more points from Laurus Labs Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Laurus Labs Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Capex guidance for FY '27 raised from INR1,500 crores to INR2,000 crores to meet customer demand and capacity expansion for multiple products and modalities (both small molecules and large peptides).
  • Majority of the capex is targeted towards small molecule APIs and CDMO capacities.
  • The company expects to invest significantly over FY '27 and FY '28, with indications that total capex for these two years may exceed INR3,000 crores.
  • Investments are also ongoing in advanced biologics, including gene therapy, ADCs, and cell and gene therapy through technology licensing and partnerships (e.g., with Aarvik Therapeutics), which are expected to yield returns over 3-5 years.

2 more points from Laurus Labs Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

Planned

See what Laurus Labs Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

Rising
  • The company handles a broad CDMO pipeline with both small and large-scale projects, with value of each program considered more important than the number of programs.
  • CDMO business is well diversified with no single product or customer contributing significantly.
  • The company has commercial programs and late-stage clinical projects, including approved products and those preparing for launch.
  • Capital expenditure is closely aligned to specific customer needs and products requiring near-term capacity expansion.

2 more points from Laurus Labs Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Laurus Labs Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Laurus Labs Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Laurus Labs Ltd announcements

All announcements →

Financials of Laurus Labs Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Laurus Labs Ltd

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +27.18%27.18%27.18%27.18%27.62%27.62%27.60%27.60%27.49%27.49%27.47%27.47%
FIIs +25.39%25.98%25.67%26.08%25.56%25.51%25.70%26.17%26.52%25.82%28.00%30.84%
DIIs +11.13%11.78%13.56%13.05%12.74%11.78%11.94%11.72%12.42%13.96%13.73%11.86%
Public +36.30%35.07%33.59%33.69%34.09%35.09%34.78%34.52%33.57%32.73%30.79%29.85%
No. of Shareholders3,82,8803,56,8303,24,0593,09,0632,92,2142,92,9052,80,2232,83,6782,80,7562,92,2812,91,6533,11,892

Financials of Laurus Labs Ltd

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +1,2241,1951,4401,1951,2241,4151,7201,5701,6531,7781,8122,0262,206
Expenses +1,0371,0141,1981,0241,0451,1301,3001,1871,2501,2981,2991,3881,456
Operating Profit188181241171178285421382403480512638750
OPM %15%15%17%14%15%20%24%24%24%27%28%32%34%
Other Income +2219359591027612913
Interest42515049535856524039404244
Depreciation9398102106108106110117120121122124127
Profit before tax54351071823131312224270327361481592
Tax %27%27%30%34%22%31%25%28%28%22%22%25%26%
Net Profit +372375132093233162194252282362436
EPS in Rs0.690.431.400.230.371.714.333.023.614.665.176.808.17

Financials of Laurus Labs Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +1,3271,7781,9052,0562,2922,8324,8144,9366,0415,0415,5546,8137,823
Expenses +1,1261,4151,4971,6421,9352,2663,2623,5124,4484,2614,4995,0285,442
Operating Profit2003624084143575651,5521,4241,5927791,0551,7852,381
OPM %15%20%21%20%16%20%32%29%26%15%19%26%30%
Other Income +34432291552314624754740
Interest10611110080889068102165183216171166
Depreciation6286106125164187205251324385430480494
Profit before tax671692342371202941,3011,0841,1092364841,1821,761
Tax %-2%21%19%29%22%13%24%23%28%29%27%25%
Net Profit +68134190168942559848327931623588901,332
EPS in Rs2.204.243.603.161.764.7718.3315.4014.672.986.6416.4624.80
Dividend Payout %-0%2%8%9%17%10%11%13%14%27%18%12%

Financials of Laurus Labs Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital1616106106106107107107108108108108108
Reserves6407741,2251,3771,4521,6632,4903,2443,9304,0034,3655,1925,953
Borrowings +8881,0948429801,0361,0791,4821,7772,0152,5772,7642,5182,625
Other Liabilities +3453394815547379011,6711,8401,6081,6992,0992,6932,828
Total Liabilities1,8882,2242,6533,0173,3313,7505,7516,9687,6608,3879,33610,51111,514
Fixed Assets +8011,0211,2301,4811,6291,7262,1712,6523,4093,8904,1234,3714,351
CWIP11070143163110673628135514234587731,282
Investments77333333150124233309310
Other Assets +9701,1261,2771,3691,5891,9533,2143,4723,6513,9504,5215,0585,570
Total Assets1,8882,2242,6533,0173,3313,7505,7516,9687,6608,3879,33610,51111,514

Financials of Laurus Labs Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-651823323422983477339119946666021,624
Cash from Investing Activity +-397-312-289-384-253-221-941-914-997-822-680-1,086
Cash from Financing Activity +486103-5442-45-12825530-2725039-525
Net Cash Flow24-27-101-0-14727-3093-3913
Free Cash Flow-447-14455-494412549346-1061560
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit-24%59%94%98%91%68%62%77%80%99%70%107%

Financials of Laurus Labs Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days78911091011131029910096120132115
Inventory Days210176186201201234266293222277285317
Days Payable102909610714415919914694158141170
Cash Conversion Cycle186178199195170177166247224240276263
Working Capital Days-0193-11615434359424358
ROCE %14%16%16%14%8%14%40%26%23%7%9%18%

Guidance history

How Laurus Labs Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →20–40%FlatPlannedPlannedRising
Q4 FY26 call →10–20%FlatPlannedPlannedRising
Q3 FY26 call →20–40%FlatPlannedNone planned—
Q2 FY26 call →20–40%FlatPlannedPlannedRising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

96out of 100

Momentum score · price trend

96 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+147.9%96%
Last 6 months+118.5%98%
Last 3 months+32.4%93%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Laurus Labs Ltd: 0.4 × 96 + 0.4 × 98 + 0.2 × 93 = 96.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Laurus Labs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Accretion Pharmaceuticals Ltd (Q2 FY27)

    25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Sigachi Industries Ltd (Q2 FY27)

    Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation

  • Advanced Enzyme Technologies Ltd (Q2 FY27)

    Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym

  • IOL Chemicals (Q2 FY27)

    Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd